simply blood

In a bid to connect the research being published in  Experimental Hematology  with the wider hematological community, we have begun to identify related pairs of recently published articles from other journals and in this entry, we focus on an article published in the European Hematology Association's journal  HemaSphere. Molecular insight into Diamond-Blackfan anemia (DBA), and a detection strategy for clinical diagnosis of DBA and other inherited bone marrow failure syndromes Inherited bone marrow failure syndromes (IBMFs) are a group of complex genetic diseases that display comparable major complications such as (pan)cytopenia, bone marrow failure, and increased risks for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Although a majority of patients receive proper diagnoses, many patients lack specific syndromic diagnoses in part due to incomplete identification of the underlying etiology of IBMFs. Therefore, further studies into the genetic, molecular, and clin

Dear Friends and Colleagues, I write this message reflecting upon what was an unprecedented time for hematology and hematology researchers. Looking back on last year, I am truly amazed by how our Society reacted to our member’s experiences with lab shutdowns, socioeconomic upheaval in reaction to political injustice, travel restrictions and economic hardships. This period may compare to the years in which the society was founded (early 1970s), when concerns about nuclear disasters fueled radiation research, hematology and the further development of concepts around hematopoietic stem cell biology. Not only did we come together as a community this last year and implement many new initiatives to support our members, but we re-organized our annual meeting with short notice to adapt to the new virtual reality, and now are forging ahead with a new improved ISEH virtual 2.0 meeting for 2021. In this last year, many of our members have also independently developed new meeting and seminar forum

In 2012, Dr. Rossi was the inaugural New Investigators Invited Speaker at the 41st Annual Scientific Meeting of ISEH. He generously agreed to be interviewed by a member of the New Investigator Committee about his captivating career path and successes in translating discoveries to the clinic. Among Dr. Rossi’s numerous accomplishments, we can list the development of an approach to generate induced pluripotent stem cells (IPSCs) using synthetic modified messenger RNA, which was named by Time magazine as one of the top ten medical breakthroughs of 2010. Dr. Rossi leveraged that technology to found Moderna Therapeutics, which is now a major supplier of vaccines against COVID-19. In 2015, Dr. Rossi co-founded Intellia Therapeutics, a publicly traded Cambridge-based company focused on developing CRISPR/Cas9-based therapeutics. In 2016, he co-founded Magenta Therapeutics, which is focused on transforming hematopoietic stem cell transplantation. In 2017, he helped launch Convelo Therapeutics,

Exploring Experimental Hematology : AMD3100 re-dosing fails to repeatedly mobilize hematopoietic stem cells in the non-human primate and humanized mouse Introduction: In this issue of Simply Blood, we are highlighting and deconstructing one of the journal’s latest manuscripts by first author Clare Samuelson. In a recent study in the laboratory of Dr. Hans-Peter Kiem (Fred Hutchinson Cancer Research Center), Samuelson et al. examined the mobilization of hematopoietic stem/ progenitor cells (HSPCs) with repeated doses of AMD3100 (plerixafor). ( Samuelson et al., 2020 ). Stem cell transplantation (SCT), using bone marrow (BM) or mobilized peripheral blood (PB) HSPCs, is a therapy used to cure several cancers, including multiple myeloma, leukemia, lymphomas, and non-malignant hematological diseases. HSPCs are enriched in the PB using a mobilization agent(s), which is a non-invasive procedure compared to a BM harvest and may offer faster hematopoietic reconstitution. AMD3100 (plerixafor) is

“I am afraid that the opinion remains that the paper is not a strong candidate for publication…” Rejection. Failure. Almost everyone will experience a mixture of these during one’s lifetime. But for a scientist, this has become the norm of our existence: failed scientific experiments, rejected grants, and scathing remarks from manuscript reviewers. The one thing that is certain in academia, is that you will have many failures; what is not as certain is one’s response to such adversity. I hope this piece can give practical advice on how to overcome ‘failure’ and even potentially change our perspective on what failure is, with an emphasis on what steps young scientists, such as graduate students who are just beginning their journey, can take. Turning your ‘negative’ response into a therapeutic one Our typical response to rejection in science (and most other endeavors) is an initial combination of anger and/or disappointment, that can progress to self-pity, blaming the ‘system’, and depre

In a bid to connect the research being published in Experimental Hematology with the wider hematological community, we have begun to identify related pairs of recently published articles from other journals and in this entry, we focus on an article published in the European Hematology Association's journal HemaSphere. Novel approaches to understanding ALL treatment and subclone diversity Acute lymphoblastic leukemia (ALL) results from malignant transformation of lymphoid progenitor cells, and is a blood cancer found predominantly in the pediatric population. Clinical prognosis for children diagnosed with ALL are amongst the best outcomes for all blood cancers, with about 90% of all patients surviving their disease. However, the remaining children who are refractory to therapy or suffer relapse still represent a significant clinical problem due to the high incidence of this disease in the pediatric population. As such, there remains tremendous importance in identifying the molec